NDSN · Q2 2026 Earnings
BullishNordson Corporation
Reported May 20, 2026
30-second summary
Nordson delivered 8.5% revenue growth to $741M, 7% organic, with all three segments and all three regions positive — and raised full-year sales and EPS guidance on the back of an 18% YoY backlog build. Management's language was atypically confident for a precision technology supplier: they framed midpoint as their base case and said only a "meaningful slowdown" gets them to the low end. The electronics/semi inflection in ATS (10.1% growth) and a medical recovery (back to 8% from a soft Q1) are doing the work.
Headline numbers
EPS
Q2 FY2026
$2.86
Revenue
Q2 FY2026
$0.74B
+8.5% YoY
Gross margin
Q2 FY2026
54.5%
Operating margin
Q2 FY2026
26.6%
Key financials
Q2 FY2026| Metric | Q2 FY2026 | YoY |
|---|---|---|
| Revenue | $0.74B | +8.5% |
| EPS | $2.86 | — |
| Gross margin | 54.5% | — |
| Operating margin | 26.6% | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment KPIs
Q2 FY2026| Segment | Q2 FY2026 | YoY |
|---|---|---|
| Industrial Precision Solutions | $0.35B | +9.9% |
| Medical and Fluid Solutions | $0.213B | +5.0% |
| Advanced Technology Solutions | $0.178B | +10.1% |
Other KPIs
Q2 FY2026| Segment | Q2 FY2026 | YoY |
|---|---|---|
| Americas | $0.308B | +5.4% |
| Europe | $0.194B | +12.7% |
| Asia Pacific | $0.238B | +9.2% |
| EBITDA | $235.2 million | — |
| EBITDA Margin | 31.7% | — |
| Backlog Growth YoY | +18% | — |
| Organic Sales Growth | 6.6% | — |
| IPS EBITDA Margin | 35.3% | — |
| Medical and Fluid Solutions EBITDA Margin | 37.1% | — |
| Advanced Technology Solutions EBITDA Margin | 27.2% | — |
| Free Cash Flow Conversion | 119% | — |
Management tone
Management spoke with notably more conviction than the typical precision-tools script. Rather than the usual "we're watching macro carefully" hedge, they inverted the framing — midpoint is the base case, downside requires a macro shock. "We have a high level of confidence in the midpoint of our range, and it would take a meaningful slowdown in order activity driven by macro conditions to move us towards the low end." That's a guidance-raise call structured to push consensus toward the upper half.
Medical shifted from a Q1 concern into a recovery story. Management characterized the segment as "steadily returning to normalized growth" with long-term drivers (aging population, minimally invasive procedures, biopharma diagnostics) reiterated as intact. The 8% segment growth print in Q2 (Somerville Q&A) versus a "modest" Q1 frames this quarter as the pivot.
The portfolio-mix narrative is being repositioned as structural rather than cyclical. "More than 50% of our portfolio is now in growth end markets, including semiconductor, electronics, and medical, with remaining exposures in more stable GDP plus end markets." This is management asking investors to re-rate the cyclicality of the business — moving away from the industrial-discretionary bucket.
Incremental margin expectations were actively reset downward. Management was explicit in Q&A that ~50% incremental conversion isn't realistic this year given inflation and tariffs, and that the focus is maintaining margin rather than expanding it. The honesty here — pre-empting the "why aren't incrementals at historical levels" question — was deliberate expectation management against a raised top-line.
FX flipped from H1 tailwind to H2 neutral, which management called out unprompted. "At current exchange rates, foreign exchange, which has been a contributor to the growth in the first half, will be essentially neutral in the second half year over year." This matters because the FY raise is therefore organic-driven, not currency-driven — a higher-quality raise than the surface print suggests.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Matt Somerville · DA Davidson
Can management confirm medical segment growth is sustainably on track for 6-8% normalized growth rates? What details can be provided on the interventional product headwind and material change impact?
Medical achieved 8% growth in Q2 and is tracking toward normalized 6-8% growth rates. The interventional product headwind is a near-term regulatory-required material change causing operational inefficiencies, with clear line of sight to resolution. Strong order entry and backlog build in medical supports confidence in normalized growth return.
Walter Liptak · Seaport Research
Can management quantify ATS order strength (single vs double digit growth)? Why is the transition from electronics dispense to test & inspection showing apparent lag?
Backlog up 18% with particular strength in ATS segment, implying double-digit order growth at least in line with or better than 18% overall. No actual lag between dispense and T&I; dispense has more units per line than T&I historically. Both businesses seeing similar demand levels; current strength in dispense is mix-driven, not market-driven.
Jeff Hammond · KeyBank Capital Markets, Inc.
What is driving the splat-down margins in industrial despite decent growth? What about price-cost and mix dynamics? How will margins trend in H2?
IPS delivered 4% organic growth with best-in-class margins for the company. Inflationary environment (including tariffs) impacting all businesses. Managing through selective pricing and cost offsets. Short-term issue; focus is maintaining margin performance while maximizing growth, not expanding margins in inflationary environment. Incrementals in 50% range not realistic this year.
Mike Halloran · Baird
Is guidance assuming sequential normalcy Q3-Q4, or is there flattening expected? What are backlog conversion timelines and any signs of capacity-driven backlog buildout, especially in ETS?
No fundamental change in backlog conversion; majority turns within six months, some within quarter, minority bleeding into 2027. Good visibility to Q3 with 60% consumables/single-use business. Prudent on Q4 due to macro dynamics (potential raw material shortages, broader pullback risk), but no pullback seen yet in demand patterns. Not taking in one-year-out orders.
What to watch into next quarter
Whether ATS revenue growth sustains at or above 10% — management implicitly tied FY upper-end delivery to electronics/semi momentum continuing
Whether the medical interventional startup headwind reverses to a tailwind in Q3-Q4, or if margin compression persists past Q2
Q3 organic growth print versus the ~6-7% Q2 run-rate, and whether backlog conversion delivers the $760-790M revenue band
IPS incremental margin trajectory — management has guided away from 50%+ but the actual incremental needs to clear the Q1 baseline (Q2 was already +300bps improvement vs Q1)
Order entry momentum in Q4 — Halloran's question on whether prudence on Q4 reflects actual softening or just conservatism; first signs of any customer order pull-back
Sources
- NDSN Q2 FY2026 press release (8-K Ex. 99.1), filed 2026-05-20
- NDSN Q2 FY2026 earnings call transcript
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.